Premium
Serum hepcidin and growth differentiation factor‐15 ( GDF ‐15) levels in polycythemia vera and essential thrombocythemia
Author(s) -
Tarkun Pinar,
Mehtap Ozgur,
Atesoğlu Elif B.,
Geduk Ayfer,
Musul Mahmut M.,
Hacihanefioglu Abdullah
Publication year - 2013
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12150
Subject(s) - essential thrombocythemia , polycythemia vera , gdf15 , medicine , endocrinology , immunology
Objectives Hepcidin plays a regulatory role in systemic iron homeostasis. GDF ‐15 has been found to be expressed from matured erythroblasts and very high levels of GDF ‐15 suppresses hepcidin secretion. In this study, we evaluated hepcidin and GDF ‐15 levels in polycythemia vera ( PV ) and essential thrombocythemia ( ET ). Methods The study included 29 patients and 21 healthy controls. The patient group included 13 patients with ET and 16 patients with PV . Serum hepcidin and GDF ‐15 levels were measured at the time of diagnosis, before the initiation of any therapy. Results Hepcidin levels did not differ significantly in patients with chronic myeloproliferative disease ( CMPD ) and healthy controls. However, GDF ‐15 levels were significantly increased in patients with CMPD ( P = 0.038). No difference could be found between patients with PV and ET in terms of hepcidin and GDF ‐15 levels. Patients with JAK 2‐V617F mutation had increased GDF ‐15 levels when compared with patients without this mutation ( P : 0.006). Conclusions The levels of GDF ‐15 were higher in CMPD , which are characterized by increased erythropoiesis, and this effect was more pronounced particularly in individuals with JAK 2‐V617F mutation. Hepcidin levels were not suppressed despite the increased erythroid activity and GDF ‐15 levels may be protective against the clinical complications of the disease such as thrombosis. This study revealed that, hepcidin levels were not suppressed despite increased erythroid activity and high GDF ‐15 levels in CMPD . We hypothesized that, this may be an attempt to prevent further amplification of erythropoietic activity by reducing iron utilization.